Mindtree Names Klaus Seifert Head Of Strategy For Europe & Chief Business Officer For DACH

Mindtree has made several key executive appointments in Europe and Asia-Pacific to further accelerate growth in the two markets. Klaus Seifert has been appointed as Head of Strategy for Europe and Chief Business Officer for Germany, Austria, and Switzerland. He was formerly the head of Global Technology Services for DACH at IBM.

Mindtree also appointed Erik Julius Larsen as Chief Business Officer for Nordics and Benelux. Prior to joining the company, he worked at Cognizant as Country Manager and Head of Sales for Nordics.

Mindtree has appointed Dominic Del Giudice as Chief Business Officer for Asia-Pacific. He was Vice President and Senior Partner at IBM Global Business Services across Asia-Pacific and Australia/New Zealand.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's Cyltezo as the first interchangeable biosimilar to AbbVie's top-selling drug Humira or adalimumab. Cyltezo, originally approved in August 2017, is both biosimilar to, and interchangeable with Humira for Cyltezo's approved uses. The Food and Drug Administration may be planning to allow people to receive Covid-19 vaccine booster shot that is different from the initial dose, reports indicate. The agency is likely to make the announcement on mix and match approach on coronavirus booster vaccines on Wednesday. The move will be part of FDA's expected authorization of boosters for the Moderna and Johnson & Johnson vaccines. Drug major Johnson & Johnson on Tuesday raised again its forecast for fiscal 2021 earnings and sales, which are above market view, after reporting higher results in the third quarter. The company's quarterly adjusted earnings also beat market estimates. In pre-market activity on the NYSE, JNJ shares were gaining around 1.24 percent to trade at $162.10.
Follow RTT